Insider transactions

EDGAR

Immunome, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-16.

Open-market purchases (code P)
11 transactions, 111,468 shares
Sum of shares × price per share: 2,305,989.79
Open-market sales (code S)
28 transactions, 1,228,648 shares
Sum of shares × price per share: 27,508,460.88

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 86

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-11 Filed 2026-09-15Higgins Jack Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,0001.35
24,300

Derived: shares × price per share. Exact value 24300.00.

78,250Direct (D) Yes— Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Higgins Jack Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)13,20025.32
334,224

Derived: shares × price per share. Exact value 334224.00.

65,050Direct (D) Yes
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Higgins Jack Officer: Chief Scientific Officer
G

Bona fide gift

Common Stock
Disposed (D)8,8000—56,250Direct (D) Yes— Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Higgins Jack Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (18,000) — exercise price 1.35
Acquired (A)18,0000—133,840Direct (D) Yes
F3
  • F3 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-12Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)11,04827.25
301,058

Derived: shares × price per share. Exact value 301058.00.

92,211Direct (D) Yes
F5
  • F5 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.
Open filing 0001808343-26-000010 Read from the filing’s XML Dispute this row
2026-08-11 Filed 2026-08-12Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)62,29126.23
1,633,892.93

Derived: shares × price per share. Exact value 1633892.93.

0Indirect (I) See footnoteYes
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000010 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10,12526.07
263,958.75

Derived: shares × price per share. Exact value 263958.75.

62,291Indirect (I) See footnoteYes
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000010 Read from the filing’s XML Dispute this row
2026-08-07 Filed 2026-08-10Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,24826.06
397,362.88

Derived: shares × price per share. Exact value 397362.88.

72,416Indirect (I) See footnoteYes
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000009 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-10Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20,84026.06
543,090.4

Derived: shares × price per share. Exact value 543090.40.

87,664Indirect (I) See footnoteYes
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000009 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)50,36612.92
650,728.72

Derived: shares × price per share. Exact value 650728.72.

50,366Direct (D) Yes— Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)40,25010.60
426,650

Derived: shares × price per share. Exact value 426650.00.

90,616Direct (D) Yes— Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Horn Kinney Officer: CHIEF BUSINESS OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)90,61625.09
2,273,555.44

Derived: shares × price per share. Exact value 2273555.44.

0Direct (D) Yes
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
  • F2 The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (50,366) — exercise price 12.92
Disposed (D)50,3660—78,542Direct (D) Yes
F3
  • F3 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (40,250) — exercise price 10.60
Disposed (D)40,2500—120,750Direct (D) Yes
F4
  • F4 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.
Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)38,2500—43,805Direct (D) No
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001831144-26-000002 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (76,500) — exercise price 22.01
Acquired (A)76,5000—76,500Direct (D) No
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001831144-26-000002 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Tsai Philip Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)38,2500—81,550Direct (D) No
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0002026600-26-000002 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Tsai Philip Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (76,500) — exercise price 22.01
Acquired (A)76,5000—76,500Direct (D) No
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0002026600-26-000002 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Horn Kinney Officer: CHIEF BUSINESS OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)31,2500—31,250Direct (D) No
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001831215-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Horn Kinney Officer: CHIEF BUSINESS OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (62,500) — exercise price 22.01
Acquired (A)62,5000—62,500Direct (D) No
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001831215-26-000004 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Rosett Max Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)47,2500—101,287Direct (D) No
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001994071-26-000006 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Rosett Max Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (94,500) — exercise price 22.01
Acquired (A)94,5000—94,500Direct (D) No
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001994071-26-000006 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Lechleider Robert Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)54,0000—69,805Direct (D) No
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001997584-26-000006 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Lechleider Robert Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (108,000) — exercise price 22.01
Acquired (A)108,0000—108,000Direct (D) No
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001997584-26-000006 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27SIEGALL CLAY B Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)180,0000—870,704Direct (D) No
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001167496-26-000005 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27SIEGALL CLAY B Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (360,000) — exercise price 22.01
Acquired (A)360,0000—360,000Direct (D) No
F2
  • F2 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001167496-26-000005 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Higgins Jack Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)38,2500—60,250Direct (D) No
F1
  • F1 Represents the number of shares of the Issuer's common stock (Common Stock) underlying restricted stock units (RSUs). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001993684-26-000006 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-07-27Higgins Jack Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (76,500) — exercise price 22.01
Acquired (A)76,5000—76,500Direct (D) No
F3
  • F3 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Open filing 0001993684-26-000006 Read from the filing’s XML Dispute this row
2026-07-07 Filed 2026-07-09Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,09212.92
14,108.64

Derived: shares × price per share. Exact value 14108.64.

1,092Direct (D) Yes— Open filing 0001831215-26-000002 Read from the filing’s XML Dispute this row
2026-07-07 Filed 2026-07-09Horn Kinney Officer: CHIEF BUSINESS OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,09225
27,300

Derived: shares × price per share. Exact value 27300.

0Direct (D) Yes
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
Open filing 0001831215-26-000002 Read from the filing’s XML Dispute this row
2026-07-07 Filed 2026-07-09Horn Kinney Officer: CHIEF BUSINESS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (1,092) — exercise price 12.92
Disposed (D)1,0920—128,908Direct (D) Yes
F2
  • F2 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
Open filing 0001831215-26-000002 Read from the filing’s XML Dispute this row
2026-07-07 Filed 2026-07-07Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)16,90624.20
409,125.2

Derived: shares × price per share. Exact value 409125.20.

108,504Indirect (I) See footnoteYes
F1, F4, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F4 The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000007 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-07Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)83,09424.11
2,003,396.34

Derived: shares × price per share. Exact value 2003396.34.

125,410Indirect (I) See footnoteYes
F1, F2, F3
  • F1 The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC (ABHMC) on March 31, 2026.
  • F2 The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F3 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000007 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-07Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)55,0008.73
480,150

Derived: shares × price per share. Exact value 480150.00.

70,805Direct (D) Yes— Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-07Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)22,71421.95
498,572.3

Derived: shares × price per share. Exact value 498572.30.

48,091Direct (D) Yes
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F2 The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-07Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)16,21422.76
369,030.64

Derived: shares × price per share. Exact value 369030.64.

31,877Direct (D) Yes
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F3 The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-07Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)16,07223.44
376,727.68

Derived: shares × price per share. Exact value 376727.68.

15,805Direct (D) Yes
F1, F4
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F4 The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-07Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (55,000) — exercise price 8.73
Disposed (D)55,0000—290,000Direct (D) Yes
F5
  • F5 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-02Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)75,66522.35
1,691,112.75

Derived: shares × price per share. Exact value 1691112.75.

232,839Indirect (I) See footnoteYes
F1, F6, F7
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F6 The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000005 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-02Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)24,33523.33
567,735.55

Derived: shares × price per share. Exact value 567735.55.

208,504Indirect (I) See footnoteYes
F1, F8, F7
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F8 The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F7 ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000005 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Barchas Isaac Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)101,05021.12
2,134,176

Derived: shares × price per share. Exact value 2134176.00.

308,504Indirect (I) See footnotesYes
F1, F2, F3, F4, F5
  • F1 The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC (ABHMC) and Arsenal Bridge Venture II-B LLC (ABV II-B), each on March 31, 2026.
  • F2 The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.
  • F3 The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • F4 The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC (ABV II) and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.
  • F5 The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
Open filing 0001808343-26-000005 Read from the filing’s XML Dispute this row
2026-06-25 Filed 2026-06-29Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)55,0008.73
480,150

Derived: shares × price per share. Exact value 480150.00.

70,805Direct (D) Yes— Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row
2026-06-25 Filed 2026-06-29Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)40,58019.56
793,744.8

Derived: shares × price per share. Exact value 793744.80.

30,225Direct (D) Yes
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F2 The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row
2026-06-25 Filed 2026-06-29Lechleider Robert Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)14,42020.66
297,917.2

Derived: shares × price per share. Exact value 297917.20.

15,805Direct (D) Yes
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
  • F3 The weighted average sale price for the transaction report was $20.66, and the range of prices were between $20.275 and $21.02, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row
2026-06-25 Filed 2026-06-29Lechleider Robert Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (55,000) — exercise price 8.73
Disposed (D)55,0000—345,000Direct (D) Yes
F4
  • F4 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Rosett Max Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)60,0001.05
63,000

Derived: shares × price per share. Exact value 63000.00.

114,037Direct (D) Yes— Open filing 0001994071-26-000004 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Rosett Max Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)60,00018.23
1,093,800

Derived: shares × price per share. Exact value 1093800.00.

54,037Direct (D) Yes
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
  • F2 The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Open filing 0001994071-26-000004 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Rosett Max Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (60,000) — exercise price 1.05
Disposed (D)60,0000—0Direct (D) Yes
F3
  • F3 The option is fully vested.
Open filing 0001994071-26-000004 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12WAGENHEIM PHILIP Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (9,897) — exercise price 18.16
Acquired (A)9,8970—9,897Direct (D) No
F1
  • F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Open filing 0001405684-26-000003 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12BIENAIME JEAN JACQUES Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (right to buy) — underlying Common Stock (9,897) — exercise price 18.16
Acquired (A)9,8970—9,897Direct (D) No
F1
  • F1 The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Open filing 0001221590-26-000018 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Vanguard Capital Management Common Stock5.045,725,57809/30/2026 Filed 2026-10-30SCHEDULE 13GOpen filing 0002100119-26-001633 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK17.419,676,88306/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001897612-26-000609 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.0001 per share4.34,832,279.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005205 Dispute this row
Alex Silverstein Common Stock, par value $0.0001 per share4.34,832,279.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005205 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.0001 per share6.16,895,000.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003222 Dispute this row
Alex Silverstein Common Stock, par value $0.0001 per share6.16,895,000.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003222 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK14.516,364,01103/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001897612-26-000495 Dispute this row
Redmile Group, LLC Common Stock, $0.0001 par value per share4.95,558,885.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-062570 Dispute this row
Jeremy C. Green Common Stock, $0.0001 par value per share4.95,558,885.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-062570 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003480 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003480 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share00.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003480 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 3Open filing 0000102909-26-000422 Dispute this row
Redmile Group, LLC Common Stock, $0.0001 par value per share5.25,718,385.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-016437 Dispute this row
Jeremy C. Green Common Stock, $0.0001 par value per share5.25,718,385.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-016437 Dispute this row
Enavate Sciences GP, LLC Common Stock, par value $0.0001 per share4.34,768,583.0012/18/2025 Filed 2025-12-22SCHEDULE 13D/AAmendment 2Open filing 0001953107-25-000019 Dispute this row
Immunome Aggregator, LP Common Stock, par value $0.0001 per share4.34,768,583.0012/18/2025 Filed 2025-12-22SCHEDULE 13D/AAmendment 2Open filing 0001953107-25-000019 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK12.210,644,67410/31/2025 Filed 2025-11-07SCHEDULE 13GOpen filing 0001897612-25-000510 Dispute this row
FMR LLC COMMON STOCK15.013,056,709.1109/30/2025 Filed 2025-10-07SCHEDULE 13G/AAmendment 1Open filing 0000315066-25-002307 Dispute this row
Abigail P. Johnson COMMON STOCK15.013,056,709.1109/30/2025 Filed 2025-10-07SCHEDULE 13G/AAmendment 1Open filing 0000315066-25-002307 Dispute this row
FMR LLC COMMON STOCK7.16,167,666.0006/30/2025 Filed 2025-08-06SCHEDULE 13GOpen filing 0000315066-25-002061 Dispute this row
Abigail P. Johnson COMMON STOCK7.16,167,666.0006/30/2025 Filed 2025-08-06SCHEDULE 13GOpen filing 0000315066-25-002061 Dispute this row
The Vanguard Group Common Stock5.204,524,95206/30/2025 Filed 2025-07-29SCHEDULE 13GOpen filing 0000932471-25-000844 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,092,408 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024185,386
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to Immunome, Inc.